US Food and Drug Administration Approval of Ciprofloxacin Hydrochloride for Management of Postexposure Inhalational Anthrax
Open Access
- 1 August 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (3) , 303-308
- https://doi.org/10.1086/421491
Abstract
In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalatiKeywords
This publication has 16 references indexed in Scilit:
- Safety of Long‐Term Therapy with Ciprofloxacin: Data Analysis of Controlled Clinical Trials and ReviewClinical Infectious Diseases, 1999
- Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety reportThe Pediatric Infectious Disease Journal, 1997
- AnthraxClinical Infectious Diseases, 1994
- The Sverdlovsk Anthrax Outbreak of 1979Science, 1994
- Pharmacokinetics of ciprofloxacin in cystic fibrosisAntimicrobial Agents and Chemotherapy, 1987
- Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patientsAntimicrobial Agents and Chemotherapy, 1986
- Ciprofloxacin pharmacokinetics in patients with cystic fibrosisInfection, 1986
- INDUSTRIAL ANTHRAXAnnals of the New York Academy of Sciences, 1958
- Enterotoxæmia of sheep: Experimental reproduction of the diseaseThe Journal of Pathology and Bacteriology, 1957
- Observations on the prophylaxis of experimental pulmonary anthrax in the monkeyEpidemiology and Infection, 1956